Connect with us

CBD Stocks

This Is Why CV Sciences Inc (OTCMKTS: CVSI) Is Rated As A Buy

Published

on

CV Sciences Inc (OTCMKTS: CVSI) has lost its spark after a massive surge in the first quarter. The stock is back to where it started the year at, on the upswing losing its momentum. Price action activity has so far remained subdued in a tight $6.30 to $4.20 trading range.

CV Sciences Price Analysis

While the subdued market activity is a point of concern, CV Sciences has continued to fire on all angles when it comes to operational efficiency. Double-digit revenue growth supplemented by gross margin expansion are some of the developments that affirm a company doing well when it comes to execution of its growth strategy.

The Company has also expanded its distribution network into Food, Drug, and Mass channels as the race for accelerated sales growth continues to heat up. Amidst the developments, the stock has continued to edge lower as investors trust continue to edge lower.

CVSI Daily Chart

The recent plunge has exposed the stock to a critical support at the $4.20 level. Above the critical support level, CV Sciences remains supported for further upside action as has been the case in the recent past. Conversely, a breach of the support level could result in the stock plunging further as part of the emerging downtrend.

A rally followed by a close above the $6.30 level, on the other hand, could open the door for the stock to power higher in continuation of the long-term downtrend. As it stands, CV Sciences is likely to bounce off the critical support level, as recent developments continue to strengthen investor sentiments in the stock.

What Does CV Sciences Do?

CV Sciences operates through two segments of consumer products and specialty pharmaceuticals. The Consumer segment markets and sells consumer products containing hemp-based cannabidiol oil. The Specialty segment, on the other hand, is involved in the development of cannabinoids for the treatment of a range of medical indications.

Buy Rating Boost

Amidst the underperformance in the stock market, CV Sciences continues to elicit interest from equity research firms. Analysts from Roth Capital have initiated coverage of the stock with a ‘buy’ rating. The brokerage firm has a $9 share price target on the stock.

The bullish rating does not come as a surprise as a flurry of positive developments continues to underscore the Company’s long-term prospects. For starters, the Company is fresh from reporting an 85% increase in first-quarter sales that came in at $14.9 million.

The increase underscored the Company’s continued organic expansion into new sales channels. CV Sciences has made its products available in Food Drug and mass channels as part of an effort of diversifying its sales channels. The expansion drive has since seen the Company’s retail store, count increase to 3,308 stores nationwide.

Since the passage of the, 2018 Farm Bill in the U.S, CV Sciences has continued to register a significant interest in its hemp derived CBD category across retailers and channels. According to the CEO, Joseph Dowling, CVSI continues to experience growth in its hemp drug development program as well.

“Our drug development program remains on track, and we continue to anticipate filing an Investigational New Drug application in late 2019 / early 2020. We have the brand, the people and the unique business model focused on both consumer products and drug development to maximize our opportunity in the rapidly growing hemp CBD industry,” said Mr. Dowling.

According to the Chief Executive, CVSI is well positioned to capitalize on both growing consumer demand and benefit of enhanced regulation with the development of the hemp-based CBD market.

Headwinds

CVSI poor show in the market could be attributed to growing concerns about the widening net loss. In the first quarter, the Company generated a $9.4 million operating net loss compared to a $0.7 million operating income, generated a year ago.

In defense of the wider than expected net loss, management insists it was as a result of additional stock-based compensation and payroll expense associated with the retirement of the former CEO.

Bottom Line

While CV Sciences is trending lower, one cannot dispute the fact that its long-term prospects and growth metrics remain intact, given the developments in the CBD market. Robust revenue growth is a milestone that underscores a company in a phase of growth.

Roth Capital initiating coverage of the stock with a buy rating is another development that underscores the Company’s long-term prospects when it comes to shareholder value generation. The pullback lower in our view presents an opportunity to buy the stock at a discount.

For the latest updates on CVSI and today’s hottest MJ stocks, sign up below!

Disclosure: We have no position in CVSI and have not been compensated for this article.

CBD Stocks

Can Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) Break Out From Here?

Published

on

Isodiol International

Investors have jumped on Isodiol International Inc (CNSX:ISOL)(OTCMKTS:ISOLF) stock this month. The stock gained 62% on January 21, marking its best day so far in 2020. The stock has already gained 106% year-to-date. But do not think even for a minute that investors have warmed up to Isodiol stock for nothing. This is a stock with tremendous potential and at this point, the stock is just showing early signs of what is going to be a big breakout.

In case you are wondering why investors have started jostling for a piece of Isodiol early on in the year, this report answers that question and more. But before we delve into the details, it is important to first understand the company we’re discussing here.

About Isodiol International

Isodiol International is a Canadian company that has specialized in the making of pharmaceutical and consumer products derived from hemp. It makes CBD products derived from hemp grown and processed in the United States. Though Isodiol’s operations are currently concentrated in North America, the company has big expansion dreams. It has set its sights on expanding into Latin America, Asia, and Europe.

What exactly is drawing investors to Isodiol stock and why does it stand out as a good pick in the hemp/cannabis stock universe in 2020? The simple answer is that investors are beginning to realize Isodiol’s bright prospects as a CBD products company.

Isodiol bidding for…

Continue Reading

CBD Stocks

New Age Beverage (NASDAQ:NBEV) Solid Fundamentals Amidst Price Slump

Published

on

New Age Beverage

New Age Beverage (NASDAQ:NBEV) has taken a significant beating since the start of the year. A 60% plus slide attests to a stock under immense pressure. Amidst the underperformance in the stock market, the company has continued to do exceedingly well when it comes to core business execution and operation efficiency.

New Age Beverage Catalysts And Price Analysis

 Triple-digit revenue growth is one of the developments that continues to affirm the company’s long-term prospects. The company also remains well-positioned to generate bottom-line growth backed by robust retail channels in the U.S as well as expansion in Asia. Integration of Morinda operations in China is another development likely to continue strengthening the company’s bottom line going forward.

 A spike in implied volatility in the options market is the latest development that signals a potential turnaround in the direction of trade. Huge implied volatility indicates that trade is developing. What is clear is that the stock has taken a significant hit and may be due for a correction higher, given the improving fundamentals.

Increased activity around the $2.50 Put options could signal a potential change in the direction of trade. After the recent slide lower, the stock needs to rise and find support above the $2.40 resistance level. A rally past the $2.40 level should reaffirm New Age Beverages bounce back prospects.

Above the crucial resistance level, the stock should be on its way to the…

Continue Reading

CBD Stocks

Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) Poised For Breakout And Here’s Why

Published

on

Charlotte's Web Stock

Charlotte’s Web Stock (TSE:CWEB) (OTCMKTS:CWBHF) is currently at one of its lowest price levels in about five months. That is the result of a selloff that kicked off toward late September after the stock reached one of its highest watermarks at $23 in August.

You cannot rule out profit-taking as having contributed to the decline that has brought the stock to its current lows considering the stock pulled up from one of its lowest levels this year in July before the August breakout. A repeat of the August bull run that powered CWBHF to one of its highest price levels this year seems to be in the offing.

Firstly, after a string of declines for much of last week and early this week, CWBHF has begun showing signs of a comeback. The stock closed the last session (November 5), up. Now the stock has found immediate support at $10.9 from where it looks set for a powerful breakout as happened in March, June, and July.

In March, for instance, CWBHF bolted from a low of $13 on March 8 to reach its one-year peak of $25 in a space of fewer than 30 days on April 4. Profit-taking kicked off after that and the stock fell to around $10 in mid-June, from where it began rising again, topping $18.5 in early July. Investors again took profit and toward late July the stock was back down at around $13.5.…

Continue Reading

MJ Stocks